About
About Eisai Co., Ltd
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Visit company website
5 years, 5 months ago
Eisai Co., Ltd is currently in a long term uptrend where the price is trading 46.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.0.
Eisai Co., Ltd's total revenue sank by 3.0% to $181B since the same quarter in the previous year.
Its net income has dropped by 58.1% to $19B since the same quarter in the previous year.
Finally, its free cash flow fell by 87.0% to $2B since the same quarter in the previous year.
Based on the above factors, Eisai Co., Ltd gets an overall score of 2/5.